...
首页> 外文期刊>Canadian Journal of Physiology and Pharmacology >Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.
【24h】

Telmisartan provides protection against development of impaired vasodilation independently of metabolic effects in SHRSP.Z-Lepr(fa)/IzmDmcr rats with metabolic syndrome.

机译:Telmisartan提供了免受代谢综合征的SHRSP.Z-LEPR(FA)/ IZMDMCR大鼠的代谢效应的血管舒张的影响保护。

获取原文
获取原文并翻译 | 示例
           

摘要

Metabolic syndrome is known to facilitate the development of cardiovascular disease. We have demonstrated that mesenteric arteries of SHRSP.Z-Lepr(fa)/IzmDmcr (SHRSP-fatty) rats with metabolic syndrome display an impaired vasorelaxation response mediated by nitric oxide. We examined whether the condition could be alleviated by treatment with telmisartan, an angiotensin II type 1 (AT1) receptor antagonist with PPAR-gamma-activating properties and compared the results with those from pioglitazone, a PPAR-gamma agonist. Telmisartan (5 mg.kg(-1).day(-1)) or pioglitazone (2.5 mg.kg(-1).day(-1)) was orally administered to male SHRSP-fatty rats for 8 weeks. Serum triglyceride and cholesterol levels were determined, and the oral glucose tolerance test was performed to evaluate insulin resistance. Vasodilations in response to acetylcholine and nitroprusside were determined by wire myographs under isometric tension conditions, protein expressions of soluble guanylyl cyclase in mesenteric arteries by Western blotting, and the contents of 3-nitrotyrosine in aortas by high-performance liquid chromatography with electrochemical detection. Telmisartan exerted antihypertensive effects, while pioglitazone ameliorated metabolic abnormalities in SHRSP-fatty rats. Telmisartan increased acetylcholine- and nitroprusside-induced relaxation and soluble guanylyl cyclase protein expression in mesenteric arteries and reduced 3-nitrotyrosine content in aortas. Pioglitazone displayed no such alleviating effects on vascular functions. These findings indicate that telmisartan protects against vasodilation disturbance through anti-oxidative and -nitrative stress independently of metabolic effects in SHRSP-fatty rats with metabolic syndrome.
机译:已知代谢综合征促进心血管疾病的发展。我们已经证明,具有代谢综合征的SHRSP.Z-LEPR(FA)/ IZMDMCR(SHRSP-FATTY)大鼠的肠系膜动脉显示由一氧化氮介导的血管内延伸反应受损。我们检查了通过用PPAR-Gamma活化性能的血管素II型1(AT1)受体拮抗剂的血管素II型1(AT1)受体拮抗剂治疗是否可以通过治疗来缓解条件。与来自吡格列酮的那些,PPAR-γ激动剂的结果进行比较。 Telmisartan(5 mg.kg(-1)。日(-1))或吡格列酮(2.5 mg.kg(-1)。日(-1))口服给予男性shrp-fatty大鼠8周。确定血清甘油三酯和胆固醇水平,进行口腔葡萄糖耐量试验以评估胰岛素抗性。通过在等距张力条件下,通过蛋白质张紧条件下的蛋白质表达,通过蛋白质印迹,通过高效液相色谱法通过蛋白质印迹,通过高效液相色谱法通过蛋白质印迹,通过高效液相色谱法测定蛋白质张力条件下的蛋白质表达,通过蛋白质印迹,以及通过高效液相色谱法通过电化学检测来确定肠系膜中的蛋白质表达。 Telmisartan施加抗高血压作用,而Pioglitazone在SHRSP-脂肪大鼠中有所改善代谢异常。 Telmisartan在肠系膜动脉中增加乙酰胆碱和硝普鞘蛋白和硝化乳房诱导的弛豫和可溶性瓜丹环酶蛋白表达,并在主动脉中降低3-硝基荧光蛋白含量。吡格列酮没有显示对血管功能的缓解效果。这些发现表明,替米沙坦通过抗氧化和 - 氮化胁迫来保护血管舒张紊乱,与代谢综合征的SHRSP-脂肪大鼠中的代谢效应无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号